Genentech Says PGx-Guided Melanoma Drug Meets Primary Endpoints in Phase III Trial

The drug, an oral kinase inhibitor that targets the oncogenic BRAF V600 mutation, is being co-developed with an investigational diagnostic test from Roche Molecular Diagnostics to identify patients whose tumors carry the mutated gene.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.